Ser297

Site Information
tGDRNNssCRNyNkQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 465458

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 3 ) , HCC2279 (pulmonary) ( 1 ) , HUES-9 ('stem, embryonic') ( 2 ) , NCI-H2172 (pulmonary) ( 1 )

References
1	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
2	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
3	Guo A (2010) CST Curation Set: 5908; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin &'\|\|' Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info